Somaxon (SOMX), P&G (PG) to Evaluate Doxepin OTC Potential Through March 31st, 2012
Go back to Somaxon (SOMX), P&G (PG) to Evaluate Doxepin OTC Potential Through March 31st, 2012| Procter & Gamble (NYSE: PG) | Delayed: 145.09 +2.12 (1.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $142.97 | 52 Week High | $90.33 | |||
| Open | $143.02 | 52 Week Low | $74.01 | |||
| Day High | $145.27 | P/E | 39.11 | |||
| Day Low | $142.14 | EPS | $3.71 | |||
| Volume | 6,456,327 | |||||
| SOMAXON PHARMA (NASDAQ: SOMX) | Delayed: 3.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.00 | 52 Week High | $3.17 | |||
| Open | $3.00 | 52 Week Low | $0.22 | |||
| Day High | $3.00 | P/E | N/A | |||
| Day Low | $3.00 | EPS | $-3.05 | |||
| Volume | 300 | |||||
